IAG are attending European Crohn’s and Colitis Organisation Congress 2023
IAG’s team and collaborators will present at the European Crohn’s and Colitis Organisation Congress 2023 (ECCO 2023)
Deployment of an Artificial Intelligence Tool for Precision Medicine in Ulcerative Colitis: Preliminary Data from 8 Globally Distributed Clinical Sites
Presentation number: P777
Session date: Friday, March 3, 2023
Session time: 12:30 – 13:30
Scientific advisors and collaborators from gastroenterology and pathology departments include:
- Nancy University Hospital, Gastroenterology, Nancy, France,
- University of Chicago Medicine, Section of Gastroenterology Hepatology and Nutrition, Chicago- IL, United States,
- University Hospital of Zurich, University of Zürich, Zurich, Switzerland,
- University of British Columbia, Division of Gastroenterology, Vancouver- BC, Canada,
- University of Basel, University Hospital Basel, Basel, Switzerland,
- Chaim Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel,
- Centro Hospitalar Universitário de São João, Faculdade de Medicina da Universidade do Porto, Porto, Portugal,
- Tel Aviv Medical Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel
IAG‘s team together with Takeda Pharmaceutical support the deployment of AI in gastroenterology practices. The abstract reports how IAG’s Artificial Intelligence (AI) tool was rolled out to 8 globally distributed centres of excellence in Inflammatory Bowel Disease, specifically UC. 600 images were collected and added to the 200 images from the proof of concept phase of the project. The resulting data set generated over 43,000 characterisations that were used to further train the AI Tool in the characterisation and quantification of cell counts and tissue types and assignment of a Nancy Index disease stage score. The AI Tool was tested by comparing results with a panel of 3 expert human histopathologists and demonstrated over 90% correlation between human and AI, laying the foundations for a novel, AI driven, standardised and quantified mechanism for UC disease stage scoring.
We are pleased to collaborate with world recognised opinion leaders to leverage IAG’s advanced imaging capabilities as we study the potential of AI driven histology to benefit patients with Ulcerative Colitis, said Dr Olga Kubassova, CEO of IAG, Image Analysis Group.
Mucosal healing is an established treatment target in UC, but not all clinical sites have access to the required resources. The AI Tool has the potential to facilitate rapid, detailed histological assessment in a clinical setting for the benefit of all UC patients’ said Simon Hart, Biopartnering Director, Image Analysis Group.
About IAG, Image Analysis Group:
IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development. www.ia-grp.com
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin